DXB
DIMERIX LIMITED
$0.2300
▼ -2.13%
Market cap
$138M
Turnover
$29,089
Last price
$0.2300
Day change
-2.13%
Announcements
19
Range, past year
Open 0.520 · Low 0.155 · Now 0.230 · High 0.785
Open DXB in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
DXB momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-09-29.
Momentum quality
16/100
Wyckoff phase
Downtrend24d
Trend stage
Breakdown
1 Day
-2.1%
1 Week
-4.2%
1 Month
-17.9%
1 Year
-54.9%
RSI
37
Avg daily range
6.1%
DIMERIX LIMITED scores 16 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Breakdown.
On the Wyckoff cycle it sits in Downtrend, where it has been for 24 trading days. The weekly timeframe reads Downtrend, which agrees with the daily view.
Against the wider market it is currently underperforming and the institutional accumulation signal reads low.
Points to watch
- 60d drawdown -30.8%
- High volatility (ATR 6.1%)
- Thin liquidity
- Risk rating: Very High
- Composite downside risk elevated
Browse the whole market by signal:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highsDXB announcements
Recent price-sensitive releases.
- 2026-09-23 Dimerix Draws Down A$17M Under Non-Dilutive Funding Facility Progress Report | Debt Facility
- 2026-09-14 Dimerix DMX-652 Granted Mexican Composition of Matter Patent Progress Report
- 2026-09-04 Dimerix Secures A$34 Million Non-Dilutive Funding Facility Trading Halt Lifted | Debt Facility
- 2026-09-02 Trading Halt Trading Halt
- 2026-08-27 Appendix 4E and 2026 Annual Report Annual Report | Top 20 shareholders | Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report
- 2026-08-20 Dimerix Receives US$10M Upfront Payment from Everest Progress Report
- 2026-08-17 Dimerix Assumes Sponsorship of US IND for New Asset DMX-652 Progress Report
More Health Care stocks
Most traded in the same sector.